Pyk2

Pyk2製品

All (7)
Pyk2阻害剤 (7)
新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例
S2890	PF-562271	PF-562271 (PF-00562271) is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM in cell-free assays, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs.	Heliyon, 2024, 10(1):e23690 Nat Commun, 2023, 14(1):6270 Cell Death Dis, 2023, 14(2):135
S8032	PRT062607 (P505-15) HCl	PRT062607 (P505-15, BIIB057, PRT-2607) is a novel, highly selective Syk inhibitor with IC50 of 1 nM in cell-free assays, >80-fold selective for Syk than Fgr, PAK5, Lyn, FAK, Pyk2, FLT3, MLK1 and Zap70.	J Exp Med, 2023, 220(9)e20230054 Adv Sci (Weinh), 2023, 10(10):e2205397 J Thromb Haemost, 2023, 21(8):2236-2247
S7357	PF-562271 HCl	PF-562271 HCl is the hydrochloride salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.	Front Immunol, 2022, 13:837180 Cancers (Basel), 2022, 14(6)1537 J Biol Chem, 2022, S0021-9258(22)00119-3
S2672	PF-562271 Besylate	PF-562271 Besylate is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.	Elife, 2023, 12RP89141 bioRxiv, 2023, 2023.06.02.543509 Front Immunol, 2022, 13:837180
S2820	TAE226 (NVP-TAE226)	TAE226 (NVP-TAE226) is a potent FAK inhibitor with IC50 of 5.5 nM and modestly potent to Pyk2, ~10- to 100-fold less potent against InsR, IGF-1R, ALK, and c-Met. TAE226 (NVP-TAE226) induces apoptosis.	Theranostics, 2022, 12(3):1097-1116 Proc Natl Acad Sci U S A, 2022, 119(32):e2201328119 Cancer Res Treat, 2022, 54(3):767-781
S7644	PF-431396	PF-431396 is a dual PYK2/FAK inhibitor with IC50 of 11 nM and 2 nM, respectively.	Nat Commun, 2023, 14(1):6270 Cell Rep, 2023, 42(5):112529 J Exp Clin Cancer Res, 2021, 40(1):364
E1783^New	Conteltinib(CT-707)	Conteltinib(CT-707) is a potent multikinase inhibitor of ALK, FAK,Pyk2, showing promising anti-tumor activities. Conteltinib exhibits significant inhibitory effects on FAK with an IC50 value of 1.6 nM in vitro kinase assay.
S2890	PF-562271	PF-562271 (PF-00562271) is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM in cell-free assays, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs.	Heliyon, 2024, 10(1):e23690 Nat Commun, 2023, 14(1):6270 Cell Death Dis, 2023, 14(2):135
S8032	PRT062607 (P505-15) HCl	PRT062607 (P505-15, BIIB057, PRT-2607) is a novel, highly selective Syk inhibitor with IC50 of 1 nM in cell-free assays, >80-fold selective for Syk than Fgr, PAK5, Lyn, FAK, Pyk2, FLT3, MLK1 and Zap70.	J Exp Med, 2023, 220(9)e20230054 Adv Sci (Weinh), 2023, 10(10):e2205397 J Thromb Haemost, 2023, 21(8):2236-2247
S7357	PF-562271 HCl	PF-562271 HCl is the hydrochloride salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.	Front Immunol, 2022, 13:837180 Cancers (Basel), 2022, 14(6)1537 J Biol Chem, 2022, S0021-9258(22)00119-3
S2672	PF-562271 Besylate	PF-562271 Besylate is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.	Elife, 2023, 12RP89141 bioRxiv, 2023, 2023.06.02.543509 Front Immunol, 2022, 13:837180
S2820	TAE226 (NVP-TAE226)	TAE226 (NVP-TAE226) is a potent FAK inhibitor with IC50 of 5.5 nM and modestly potent to Pyk2, ~10- to 100-fold less potent against InsR, IGF-1R, ALK, and c-Met. TAE226 (NVP-TAE226) induces apoptosis.	Theranostics, 2022, 12(3):1097-1116 Proc Natl Acad Sci U S A, 2022, 119(32):e2201328119 Cancer Res Treat, 2022, 54(3):767-781
S7644	PF-431396	PF-431396 is a dual PYK2/FAK inhibitor with IC50 of 11 nM and 2 nM, respectively.	Nat Commun, 2023, 14(1):6270 Cell Rep, 2023, 42(5):112529 J Exp Clin Cancer Res, 2021, 40(1):364
E1783^New	Conteltinib(CT-707)	Conteltinib(CT-707) is a potent multikinase inhibitor of ALK, FAK,Pyk2, showing promising anti-tumor activities. Conteltinib exhibits significant inhibitory effects on FAK with an IC50 value of 1.6 nM in vitro kinase assay.
E1783^New	Conteltinib(CT-707)	Conteltinib(CT-707) is a potent multikinase inhibitor of ALK, FAK,Pyk2, showing promising anti-tumor activities. Conteltinib exhibits significant inhibitory effects on FAK with an IC50 value of 1.6 nM in vitro kinase assay.

Pyk2阻害剤の選択性比較